Bonesupport Holding AB (publ)

OM:BONEX Stock Report

Market Cap: SEK 19.7b

Bonesupport Holding Valuation

Is BONEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BONEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 461.71
Fair Value
34.7% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: BONEX (SEK301.6) is trading below our estimate of fair value (SEK461.71)

Significantly Below Fair Value: BONEX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BONEX?

Key metric: As BONEX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BONEX. This is calculated by dividing BONEX's market cap by their current earnings.
What is BONEX's PE Ratio?
PE Ratio134.2x
EarningsSEK 147.98m
Market CapSEK 19.69b

Price to Earnings Ratio vs Peers

How does BONEX's PE Ratio compare to its peers?

The above table shows the PE ratio for BONEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.6x
BIOA B BioArctic
26x-5.50%SEK 27.4b
VITR Vitrolife
40.8x21.74%SEK 18.5b
BIOG B BioGaia
38.4x22.48%SEK 10.7b
SOBI Swedish Orphan Biovitrum
24.9x15.81%SEK 106.7b
BONEX Bonesupport Holding
134.2x59.45%SEK 19.9b

Price-To-Earnings vs Peers: BONEX is expensive based on its Price-To-Earnings Ratio (134.2x) compared to the peer average (32.6x).

Price to Earnings Ratio vs Industry

How does BONEX's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BONEX 134.2xIndustry Avg. 20.3xNo. of Companies5PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BONEX is expensive based on its Price-To-Earnings Ratio (134.2x) compared to the European Biotechs industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is BONEX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BONEX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio134.2x
Fair PE Ratio67.8x

Price-To-Earnings vs Fair Ratio: BONEX is expensive based on its Price-To-Earnings Ratio (134.2x) compared to the estimated Fair Price-To-Earnings Ratio (67.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BONEX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 301.60
SEK 409.80
+35.88%
9.40%SEK 474.00SEK 370.00n/a5
Sep ’26SEK 317.20
SEK 419.75
+32.33%
8.79%SEK 474.00SEK 375.00n/a4
Aug ’26SEK 323.40
SEK 419.00
+29.56%
8.54%SEK 471.00SEK 375.00n/a4
Jul ’26SEK 278.00
SEK 426.00
+53.24%
7.11%SEK 474.00SEK 400.00n/a4
Jun ’26SEK 254.20
SEK 434.67
+70.99%
6.99%SEK 474.00SEK 400.00n/a3
May ’26SEK 315.80
SEK 434.67
+37.64%
6.99%SEK 474.00SEK 400.00n/a3
Apr ’26SEK 314.00
SEK 445.33
+41.83%
7.92%SEK 486.00SEK 400.00n/a3
Mar ’26SEK 385.80
SEK 445.33
+15.43%
7.92%SEK 486.00SEK 400.00n/a3
Feb ’26SEK 348.40
SEK 422.33
+21.22%
4.92%SEK 450.00SEK 400.00n/a3
Jan ’26SEK 386.80
SEK 402.33
+4.02%
2.77%SEK 417.00SEK 390.00n/a3
Dec ’25SEK 366.40
SEK 362.33
-1.11%
16.35%SEK 417.00SEK 280.00n/a3
Nov ’25SEK 336.40
SEK 345.67
+2.75%
16.22%SEK 417.00SEK 280.00n/a3
Oct ’25SEK 295.80
SEK 323.33
+9.31%
9.56%SEK 350.00SEK 280.00SEK 296.803
Sep ’25SEK 303.00
SEK 323.33
+6.71%
9.56%SEK 350.00SEK 280.00SEK 317.203
Aug ’25SEK 288.00
SEK 323.33
+12.27%
9.56%SEK 350.00SEK 280.00SEK 323.403
Jul ’25SEK 271.00
SEK 297.67
+9.84%
4.56%SEK 313.00SEK 280.00SEK 278.003
Jun ’25SEK 254.40
SEK 292.67
+15.04%
4.96%SEK 313.00SEK 280.00SEK 254.203
May ’25SEK 226.00
SEK 292.67
+29.50%
4.96%SEK 313.00SEK 280.00SEK 315.803
Apr ’25SEK 228.00
SEK 273.67
+20.03%
4.63%SEK 285.00SEK 256.00SEK 314.003
Mar ’25SEK 195.60
SEK 257.00
+31.39%
7.15%SEK 280.00SEK 235.00SEK 385.803
Feb ’25SEK 203.40
SEK 257.00
+26.35%
7.15%SEK 280.00SEK 235.00SEK 348.403
Jan ’25SEK 188.20
SEK 245.50
+30.45%
4.28%SEK 256.00SEK 235.00SEK 386.802
Dec ’24SEK 175.90
SEK 245.50
+39.57%
4.28%SEK 256.00SEK 235.00SEK 366.402
Nov ’24SEK 149.20
SEK 166.50
+11.60%
3.90%SEK 173.00SEK 160.00SEK 336.402
Oct ’24SEK 127.30
SEK 166.50
+30.79%
3.90%SEK 173.00SEK 160.00SEK 295.802
SEK 409.8
Fair Value
26.4% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 17:42
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bonesupport Holding AB (publ) is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Erik CasselDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie